Addex Therapeutics Ltd ADR (ADXN)

$7.97 +0.02 (0.25%)
Market Cap 8.42M
Revenue (ttm) 1.80M
Net Income (ttm) -11.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -653.33%
Debt to Equity Ratio 0.00
Volume 5,000
Avg Vol 45,318
Day's Range N/A - N/A
Shares Out 1.06M
Stochastic %K 42%
Beta 1.76
Analysts Strong Sell
Price Target $30.00

Latest News on ADXN

Addex to Present at the 2025 Swiss Equities Baader Conference

Jan 8, 2025, 1:00 AM EST - 10 days ago

Addex to Present at the 2025 Swiss Equities Baader Conference

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript

Nov 22, 2024, 11:11 AM EST - 2 months ago

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 22, 2024, 1:00 AM EST - 2 months ago

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Nov 11, 2024, 1:00 AM EST - 2 months ago

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript

Sep 30, 2024, 12:04 PM EDT - 3 months ago

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Sep 30, 2024, 1:00 AM EDT - 3 months ago

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Sep 19, 2024, 1:00 AM EDT - 4 months ago

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 1:00 AM EDT - 4 months ago

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

Aug 27, 2024, 12:03 PM EDT - 5 months ago

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

Why Addex Therapeutics stock skyrocketed 70% on Tuesday

Aug 27, 2024, 10:47 AM EDT - 5 months ago

Why Addex Therapeutics stock skyrocketed 70% on Tuesday

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Aug 27, 2024, 1:00 AM EDT - 5 months ago

Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration

Addex's Partner Discontinues ADX71149 development in Epilepsy

Jul 22, 2024, 1:00 AM EDT - 6 months ago

Addex's Partner Discontinues ADX71149 development in Epilepsy

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Jul 15, 2024, 1:00 AM EDT - 6 months ago

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Jul 12, 2024, 1:00 AM EDT - 6 months ago

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Addex Shareholders Approve All Resolutions at Annual General Meeting

Jul 1, 2024, 1:00 AM EDT - 7 months ago

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript

Jun 6, 2024, 12:50 PM EDT - 8 months ago

Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript

Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

Jun 6, 2024, 1:00 AM EDT - 8 months ago

Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

Addex Convenes Annual General Meeting 2024

Jun 5, 2024, 1:00 AM EDT - 8 months ago

Addex Convenes Annual General Meeting 2024

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

May 31, 2024, 1:00 AM EDT - 8 months ago

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Addex to Present at Bio€quity Europe 2024

May 8, 2024, 1:00 AM EDT - 9 months ago

Addex to Present at Bio€quity Europe 2024

Addex Provides Update on ADX71149 Phase 2 Epilepsy Study

Apr 29, 2024, 1:00 AM EDT - 9 months ago

Addex Provides Update on ADX71149 Phase 2 Epilepsy Study

Addex to Present at the Swiss Biotech Day 2024

Apr 19, 2024, 1:00 AM EDT - 9 months ago

Addex to Present at the Swiss Biotech Day 2024

Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript

Apr 18, 2024, 1:46 PM EDT - 9 months ago

Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Apr 18, 2024, 1:00 AM EDT - 9 months ago

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Apr 11, 2024, 1:00 AM EDT - 10 months ago

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Apr 3, 2024, 1:00 AM EDT - 10 months ago

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

Addex to Present at the Bio-Europe Spring 2024 Conference

Mar 14, 2024, 2:00 AM EDT - 11 months ago

Addex to Present at the Bio-Europe Spring 2024 Conference

Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.

Jan 31, 2024, 1:00 AM EST - 1 year ago

Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.

Addex to Present at the Swiss Equities Baader Conference

Jan 9, 2024, 1:00 AM EST - 1 year ago

Addex to Present at the Swiss Equities Baader Conference

Addex to Present at Biotech Showcase™ 2024

Jan 5, 2024, 1:30 AM EST - 1 year ago

Addex to Present at Biotech Showcase™ 2024

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

Dec 20, 2023, 1:00 AM EST - 1 year ago

Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

Addex Creates Treasury Shares

Dec 14, 2023, 1:00 AM EST - 1 year ago

Addex Creates Treasury Shares

Addex Therapeutics Ltd (ADXN) Q3 2023 Earnings Call Transcript

Nov 29, 2023, 1:41 PM EST - 1 year ago

Addex Therapeutics Ltd (ADXN) Q3 2023 Earnings Call Transcript

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

Nov 29, 2023, 1:00 AM EST - 1 year ago

Addex Reports Q3 2023 Financial Results and Provides Corporate Update

Addex Convenes Extraordinary General Meeting

Nov 28, 2023, 1:00 AM EST - 1 year ago

Addex Convenes Extraordinary General Meeting

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Nov 23, 2023, 1:00 AM EST - 1 year ago

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Nov 14, 2023, 1:00 AM EST - 1 year ago

Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

Addex Regains Nasdaq Listing Compliance

Nov 8, 2023, 1:00 AM EST - 1 year ago

Addex Regains Nasdaq Listing Compliance

Addex Announces Participation in the Bio-Europe 2023 Conference

Nov 2, 2023, 2:00 AM EDT - 1 year ago

Addex Announces Participation in the Bio-Europe 2023 Conference

Addex Completes ADS Ratio Change

Oct 20, 2023, 1:00 AM EDT - 1 year ago

Addex Completes ADS Ratio Change

Addex Announces Plan to Implement ADS Ratio Change

Oct 6, 2023, 4:00 PM EDT - 1 year ago

Addex Announces Plan to Implement ADS Ratio Change

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

Sep 20, 2023, 1:00 AM EDT - 1 year ago

Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 1:00 AM EDT - 1 year ago

Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

Sep 5, 2023, 1:00 AM EDT - 1 year ago

Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

Addex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain

Sep 4, 2023, 1:00 AM EDT - 1 year ago

Addex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain

Addex Therapeutics Ltd (ADXN) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 9:48 PM EDT - 1 year ago

Addex Therapeutics Ltd (ADXN) Q2 2023 Earnings Call Transcript

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 1:00 AM EDT - 1 year ago

Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

Aug 4, 2023, 1:00 AM EDT - 1 year ago

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023

Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration

Aug 3, 2023, 1:00 AM EDT - 1 year ago

Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder

Jul 24, 2023, 1:00 AM EDT - 1 year ago

Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder